Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03388-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Aranzazu Arias-Martinez und 30 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program in Pharmacy, Universidad de Granada, Barrio Verxeles n°13 2°, CP 27850, Granada, Viveiro, Spain. arantxa.91.am@gmail.com. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma, Stomach Neoplasms, Fluorouracil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platinum-based regimens' safety and synergy with combination treatments need consideration.
Methods
We analyzed cases from the AGAMENON–SEOM Spanish registry of HER2-negative advanced esophagogastric adenocarcinoma treated with platinum and fluoropyrimidine from 2008 to 2021. This study focused exclusively on patients receiving one of the four regimens: FOLFOX (5-FU and oxaliplatin), CAPOX (capecitabine and oxaliplatin), CP (capecitabine and cisplatin) and FP (5-FU and cisplatin). The aim was to determine the most effective and tolerable platinum and fluoropyrimidine-based chemotherapy regimen and to identify any prognostic factors.
Results
Among 1293 patients, 36% received either FOLFOX ( n = 468) or CAPOX ( n = 466), 20% CP ( n = 252), and 8% FP ( n = 107). FOLFOX significantly increased PFS (progression free survival) compared to CP, with a hazard ratio of 0.73 (95% CI 0.58–0.92, p = 0.009). The duration of treatment was similar across all groups. Survival outcomes among regimens were similar, but analysis revealed worse ECOG–PS (Eastern Cooperative Oncology Group–Performance Status), > 2 metastatic sites, bone metastases, hypoalbuminemia, higher NLR (neutrophil-to-lymphocyte ratio), and CP regimen as predictors of poor PFS. Fatigue was common in all treatments, with the highest incidence in FOLFOX (77%), followed by FP (72%), CAPOX (68%), and CP (60%). Other notable toxicities included neuropathy (FOLFOX 69%, CAPOX 62%), neutropenia (FOLFOX 52%, FP 55%), hand–foot syndrome in CP (46%), and thromboembolic events (FP 12%, CP 11%).
Conclusions
FOLFOX shown better PFS than CP. Adverse effects varied: neuropathy was more common with oxaliplatin, while thromboembolism was more frequent with cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Program in Pharmacy, Universidad de Granada, Barrio Verxeles n°13 2°, CP 27850, Granada, Viveiro, Spain. arantxa.91.am@gmail.com.
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain.
- Medical Oncology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.
- Medical Oncology Department, Hospital Universitario La Paz, CIBERONC, CB16/12/00398, Madrid, Spain.
- Medical Oncology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain.
Zitieren
APA
Arias-Martinez, A., Martínez de Castro, E., Gallego, J., Arrazubi, V., Custodio, A., Fernández Montes, A., Diez, M., Hernandez, R., Limón, M. L., Cano, J. M., Vidal-Tocino, R., Macias, I., Visa, L., Martin Richard, M., Sauri, T., Hierro, C., Gil, M., Cerda, P., Martínez Moreno, E., …, & Alvarez-Manceñido, F. (2024). Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03388-6
Vancouver
Arias-Martinez A, Martínez de Castro E, Gallego J, Arrazubi V, Custodio A, Fernández Montes A, et al. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03388-6
BibTeX
@article{AriasMartinez2024,
author = {Arias-Martinez, Aranzazu and Martínez de Castro, Eva and Gallego, Javier and Arrazubi, Virginia and Custodio, Ana and Fernández Montes, Ana and Diez, Marc and Hernandez, Raquel and Limón, María Luisa and Cano, Juana María and Vidal-Tocino, Rosario and Macias, Ismael and Visa, Laura and Martin Richard, Marta and Sauri, Tamara and Hierro, Cinta and Gil, Mireia and Cerda, Paula and Martínez Moreno, Elia and Martínez Lago, Nieves and Mérida-García, Antonio José and Gómez González, Lucía and García Navalón, Francisco Javier and Ruiz Martín, Maribel and Marín, Gema and López-López, Flora and Ruperez Blanco, Ana Belen and Fernández, Alejandro Francisco and Jimenez-Fonseca, Paula and Carmona-Bayonas, Alberto and Alvarez-Manceñido, Felipe},
title = {Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03388-6}
}
EUVIMED